

Online supplement

Included studies (*n* = 120)

- Ahlfors UR, Rimón B, Appelberg U, Hagert P, Harma H, Katila, et al. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. *Acta Psychiatr Scand Suppl* 1990; **358**: 99–103.
- Anil Yaciolu A, Kivircik Akdede B, Turgut T, Tumuklu M, Yazici M, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. *J Clin Psychiatry* 2005; **66**: 63–72.
- Arvanitis L, Miller B. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. *Biol Psychiatry* 1997; **42**: 233–46.
- Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. *J Clin Psychiatry* 2003; **64**: 598–604.
- Barak Y, Shamir E, Mirecki I, Weizman R, Aizenberg D. Switching elderly chronic psychotic patients to olanzapine. *Int J Neuropsychopharmacol* 2004; **7**: 165–9.
- Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. *J Clin Psychopharmacol* 2002; **22**: 115–20.
- Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. *Prog Neuropsychopharmacol Biol Psychiatry* 2002; **26**: 1199–202.
- Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacol* 1996; **14**: 111–23.
- Bitter I, Dossenbach M, Brook S, Feldman P, Metcalfe S, Gagiano C, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; **28**: 173–80.
- Blin O, Azorin J, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. *J Clin Psychopharmacol* 1996; **16**: 38–44.
- Buchanan R, Breier A, Kirkpatrick B, Ball P, Carpenter W. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. *Am J Psychiatry* 1998; **155**: 751–60.
- Casey D, Daniel D, Wassef A, Tracy K, Wozniak P, Sommerville K. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. *Neuropsychopharmacol* 2003; **28**: 182–92.
- Ceková E, Vestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. *Pharmacopsychiatry* 1993; **26**: 121–4.
- Chan H-Y, Lin W-W, Lin S-K, Hwang T-J, Su T-P, Chiang S-C, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. *J Clin Psychiatry* 2007; **68**: 29–36.
- Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol* 1993; **13**: 25–40.
- Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. *Eur Neuropsychopharmacol* 2005; **15**: 111–7.
- Ciliberto N, Bossie C, Urioste R, Lasser, R. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. *Int Clin Psychopharmacol* 2005; **20**: 207–12.
- Claus A, Bollen J, Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative trial. *Acta Psychiatr Scand* 1992; **85**: 295–305.
- Conley R, Tamminga C, Bartko J, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. *Am J Psychiatry* 1998; **155**: 914–20.
- Corrigan M, Gallen C, Bonura M, Merchant K, Sonepiprazole Study Group. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 2004; **55**: 445–51.
- Csernansky J, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. *New Engl J Med* 2002; **346**: 16–22.
- Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER) results of a 6-week, randomized, placebo-controlled study. *Schizophr Res* 2007; **93**: 117–30.
- de Jesus Mari J, Lima M, Costa A, Alexandrino N, Rodrigues-Filho S, de Oliveira I, et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. *Eur Arch Psychiatry Clin Neurosci* 2004; **254**: 356–61.
- Deo R, Soni S, Rastogi S, Levine S, Plant I, Edwards J, et al. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. *Acta Psychiatr Scand Suppl* 1990; **358**: 120–4.
- Docherty J, Bossie C, Lachaux B, Bouhours P, Zhu Y, Lasser R, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. *Int Clin Psychopharmacol* 2007; **22**: 51–5.
- Dossenbach M, Folnegovic-Smalc V, Hotujac L, Uglesic, B, Tollefson G, Grundy S, et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; **28**: 311–8.
- Ebrinc S, Semiz U, Basoglu C, Cetin M, Baykiz A, Kandilcioglu H, et al. Efficacy and safety of amisulpride treatment in schizophrenia: comparison with haloperidol [in Turkish]. *Klinik Psikofarmakoloji Bulteni* 2004; **14**: 143–9.
- Emsley R. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. *Schizophr Bull* 1999; **25**: 721–9.
- Feldman P, Kaiser C, Kennedy J, Sutton V, Tran P, Tollefson G, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. *J Clin Psychiatry* 2003; **64**: 998–1004.
- Fleischhacker W, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. *J Clin Psychiatry* 2003; **64**: 1250–7.
- Godleski L, Goldsmith L, Vieweg W, Zettwoch N, Stikovic D, Lewis S. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. *J Clin Psychiatry* 2003; **64**: 119–22.
- Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. *J Neural Transm* 2003; **110**: 545–60.
- Gureje O, Miles W, Keks K, Grainger D, Lambert T, McGrath J, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. *Schizophr Res* 2003; **61**: 303–14.
- Heck A, Haffmans P, de Groot I, Hoencamp E. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. *Schizophr Res* 2000; **46**: 97–105.
- Honer W, Thornton A, Chen E, Chan R, Wong J, Bergmann A, et al. Clozapine and Risperidone Enhancement Study Group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *New Engl J Med* 2006; **354**: 472–82.
- Hong C, Chen J, Chiu H, Sim C. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. *Int Clin Psychopharmacol* 1997; **12**: 123–30.
- Howanitz E, Pardo M, Smelson D, Engelhart C, Eisenstein N, Losonczy M. Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. *J Clin Psychiatry* 1999; **60**: 41–4.
- Høyberg O, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesan I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. *Acta Psychiatr Scand* 1993; **88**: 395–402.
- Huttunen M, Piepponen T, Rantanen R, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. *Acta Psychiatr Scand* 1995; **91**: 271–7.
- Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. *Psychiatry Clin Neurosci* 2001; **55**: 403–14.
- Itoh H, Miura S, Yagi G, Sakurai S, Ohtsuka N. Some methodological considerations for the clinical evaluation of neuroleptics-comparative effects of clozapine and haloperidol on schizophrenics. *Folia Psychiatr Neurol* 1977; **31**: 17–24.
- Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Bull* 2007; **90**: 147–61.
- Kane J, Carson W, Saha A, McQuade R, Ingenito G, Zimbroff D, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 2002; **63**: 763–71.

- Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. The Clozaril Collaborative Study Group. *Arch Gen Psychiatry* 1988; **45**: 789–96.
- Kane J, Marder S, Schooler N, Wirshing W, Umbricht D, Baker R, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. *Arch Gen Psychiatry* 2001; **58**: 965–72.
- Kane J, Meltzer H, Carson WJ, McQuade R, Marcus R, Sanchez R, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. *J Clin Psychiatry* 2007; **68**: 213–23.
- Kim K, Pae C, Chae J, Bahk W, Jun T, Kim D, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. *J Clin Psychiatry* 2002; **63**: 408–13.
- Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, et al. Direct transition to long-acting risperidone—analysis of long-term efficacy. *J Psychopharmacology* 2005; **19** (suppl 5): 15–21.
- Klieser E, Strauss W, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. *Acta Psychiatr Scand Suppl* 1994; **380**: 68–73.
- Kontaxakis V, Havaki-Kontaxaki B, Ferentinos P, Pappas K, Soldatos C. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. *Eur Psychiatry* 2006; **21**: 214–7.
- Krakowski M, Czobor P, Citrome L, Bark N, Cooper T. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry* 2006; **63**: 622–9.
- Kumra S, Frazier J, Jacobsen L, McKenna K, Gordon C, Lenane M, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. *Arch Gen Psychiatry* 1996; **53**: 1090–7.
- Lane H, Chang Y, Chiu C, Chen T, Lee S, Chang W. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. *J Clin Psychopharmacol* 2002; **22**: 353–8.
- Lane H, Chang Y, Chiu C, Lee S, Lin C, Chang W. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. *Psychopharmacol* 2004; **172**: 393–9.
- Lasser R, Bossie C, Gharabawi G, Baldessarini R. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. *Int J Neuropsychopharmacol* 2005; **8**: 427–38.
- Lasser R, Bossie C, Gharabawi G, Eerdeken M, Nasrallah H. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. *J Affect Disord* 2004; **83**: 263–75.
- Lasser R, Bossie C, Gharabawi G, Kane J. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. *Schizophr Res* 2005; **77**: 215–27.
- Lasser R, Bossie C, Gharabawi G, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. *Eur Psychiatry* 2004; **19**: 219–25.
- Lasser R, Bossie C, Zhu Y, Locklear J, Kane J. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. *Ann Clin Psychiatry* 2007; **19**: 65–71.
- Lauriello J, McEvoy J, Rodriguez S, Bossie C, Lasser R. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. *Schizophr Res* 2005; **72**: 249–58.
- Laux G, Klieser E, Schroder H, Dittmann V, Unterweger B, Schubert H, et al. A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. *Acta Psychiatr Scand Suppl* 1990; **358**: 125–9.
- Lee C, Conde B, Mazlan M, Visanuyothin T, Wang A, Wong M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. *J Clin Psychiatry* 2002; **63**: 569–76.
- Lewis S, Barnes T, Davies L, Murray R, Dunn G, Hayhurst K, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. *Schizophr Bull* 2006; **32**: 715–23.
- Lindenmayer J, Czobor P, Volavka J, Lieberman J, Citrome L, Sheitman B, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. *J Clin Psychiatry* 2002; **63**: 931–5.
- Lindenmayer J, Eerdeken E, Berry S, Eerdeken M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. *J Clin Psychiatry* 2004; **65**: 1084–9.
- Lindenmayer J, Khan A, Iskander A, Abad M, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. *J Clin Psychiatry* 2007; **68**: 368–79.
- Lindstrom L, Wieselgren I, Struwe G, Kristjansson E, Aksefson S, Arthur H, et al. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. *Acta Psychiatr Scand Suppl* 1990; **358**: 130–5.
- Lipkovich I, Deberdt W, Csernansky J, Buckley P, Peuskens J, Kollack-Walker S, et al. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. *J Psychiatr Res* 2007; **41**: 305–10.
- Llorca P, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. *J Psychiatry Neurosci* 2002; **27**: 30–7.
- Llorca P-M, Kahn J-P, Moreau-Moreau V, Bouhours P. Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable. *Int J Psychiatry Clin Pract* 2006; **10**: 276–84.
- Maciulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, et al. Efficacy and tolerability of olanzapine in patients with schizophrenia in Lithuania: a 13-week, multicenter, open-label, nonrandomized study. *Curr Ther Res* 2004; **65**: 57–69.
- Marder S, Meibach R. Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994; **151**: 825–35.
- Mauri M, Colasanti A, Rossattini M, Moliterno D, Baldi M, Papa P. A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia. *Clin Neuropharmacol* 2006; **29**: 126–31.
- Mauri M, Steinhilber C, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. *Eur Psychiatry* 2005; **20**: 55–60.
- McEvoy J, Lieberman J, Perkins D, Hamer R, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 2007; **164**: 1050–60.
- McEvoy J, Lieberman J, Stroup T, Davis S, Meltzer H, Rosenheck R, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; **163**: 600–10.
- Megna J, Kunwar A, Mahlotra K, Sauro M, Devitt P, Rashid A. Practitioner's corner. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. *J Psychiatr Pract* 2007; **13**: 129–37.
- Min S, Rhee C, Kim C, Kang, D. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. *Yonsei Med J* 1993; **34**: 179–90.
- Moller H, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. *Psychopharmacol* 1997; **132**: 396–401.
- Moller H, Llorca P, Sacchetti E, Martin S, Medori R, Parellada E. StoRMi Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. *Int Clin Psychopharmacol* 2005; **20**: 121–30.
- Mozes T, Ebert T, Michal S, Spivak B, Weizman A. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. *J Child Adolesc Psychopharmacol* 2006; **16**: 393–403.
- Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb A, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. *Acta Psychiatr Scand* 2004; **110**: 292–8.
- Naber D, Riedel M, Klimke A, Vorbach E-U, Lambert M, Kuhn K-U, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective wellbeing and clinical outcome in patients with schizophrenia. *Acta Psychiatr Scand* 2005; **111**: 106–15.
- Nick B, Vauth R, Braendle D, Riecher-Rossler A. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. *Int J Psychiatry Clin Pract* 2006; **10**: 174–81.
- Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. *Pharmacopsychiatry* 2006; **39**: 209–12.
- Orlandi V, Robone C, Bersani G. Atypical antipsychotics in patients with schizophrenia and comorbid cannabis abuse: Clinical data with olanzapine [in Italian]. *Riv Psichiatr* 2004; **39**: 356–64.
- Pajonk F, Schreiner A, Peters S, Rettig K, Degner D, Ruther E. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. *J Clin Psychopharmacol* 2006; **25**: 293–300.

- Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner M, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. *J Psychopharmacol* 2005; **19** (suppl 5): 5–14.
- Patris M, Agussol P, Alby J, Brion S, Burnat G, Castelnau D, et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. *Acta Psychiatr Scand Suppl* 1990; **358**: 78–92.
- Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. *Br J Psychiatry* 1995; **166**: 712–26.
- Peuskens J, Mertens C, Geerts S, Gillain B, Van Vleymen B. Open study evaluating the onset of antipsychotic action of olanzapine in the treatment of patients with schizophrenia, schizophreniform or schizoaffective disorder. *Int J Psychiatry Clin Pract* 2004; **8**: 199–204.
- Pflug B, Bartels M, Bauer H, Bunse J, Gallhofer B, Haas S, et al. A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia. *Acta Psychiatr Scand Suppl* 1990; **358**: 142–6.
- Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. *J Clin Psychiatry* 2003; **64**: 1048–56.
- Potkin S, Gharabawi G, Greenspan A, Mahmoud R, Kosik-Gonzalez C, Rupnow M, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. *Schizophr Res* 2006; **85**: 254–65.
- Potkin S, Saha A, Kujawa M, Carson W, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry* 2004; **60**: 681–90.
- Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. *Acta Psychiatr Scand* 1998; **98**: 65–72.
- Purdon S, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. *J Psychiatry Neurosci* 2001; **26**: 137–49.
- Raedler T, Schreiner A, Naber D, Wiedemann K. Early onset of treatment effects with oral risperidone. *BMC Psychiatry* 2007; **7**: 4.
- Riedel M, Schwarz M, Strassnig M, Spellmann I, Muller-Arends A, Weber K, et al. Risperidone plasma levels, clinical response and side-effects. *Eur Arch Psychiatry Clin Neurosci* 2005; **255**: 261–8.
- Rodriguez-Perez V, Lopez A, Blanco C, Pena C, Lopez A, Abel A, et al. Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. *Prog Neuropsychopharmacol Biol Psychiatry* 2002; **26**: 1055–62.
- Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. *New Engl J Med* 1997; **337**: 809–15.
- Rosenheck R, Leslie D, Sindelar J, Miller E, Lin H, Stroup T, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. *Am J Psychiatry* 2006; **163**: 2080–9.
- Rybakowski J, Jarema M. Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: an international multicenter study. *Int J Psychiatry Clin Pract* 2004; **8**: 147–52.
- Rybakowski J, Jarema M. Letter. *Int J Psychiatry Clin Pract* 2007; **11**: 81.
- Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y. Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month, double-blind study: correction. *Neuropsychopharmacol* 2003; **28**: 611.
- Sevinck L, Topaloglu B. Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; **30**: 141–3.
- Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. *Am J Psychiatry* 2007; **164**: 1404–10.
- Silva de Lima M, de Jesus Mari J, Breier A, Maria Costa A, Ponde de Sena E, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. *J Clin Psychiatry* 2005; **66**: 831–8.
- Stratta P, Donda P, Rossi A, Rossi A. Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. *Hum Psychopharmacol Clin Exp* 2005; **20**: 401–8.
- Strous R, Kupchik M, Roitman S, Schwartz S, Gonen N, Mester R, et al. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. *Hum Psychopharmacol Clin Exp* 2006; **21**: 235–43.
- Tollefson G, Beasley C, Tran P, Street J, Krueger J, Tamura R, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. *Am J Psychiatry* 1997; **154**: 457–65.
- Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. *Int Clin Psychopharmacol* 2004; **19**: 241–9.
- van Os J, Bossie C, Lasser R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. *Int Clin Psychopharmacol* 2004; **19**: 229–32.
- Volavka J, Czobor P, Sheitman B, Lindenmayer J, Citrome L, McEvoy J, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. *Am J Psychiatry* 2002; **159**: 255–62.
- Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. *J Psychiatr Res* 2006; **40**: 669–76.
- Wirshing D, Marshall B, Green M, Mintz J, Marder S, Wirshing W. Risperidone in treatment-refractory schizophrenia. *Am J Psychiatry* 1999; **156**: 1374–9.
- Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. *J Child Adolesc Psychopharmacol* 2003; **13**: 319–27.
- Zhang X, Zhou D, Cao L, Zhang P, Wu G, Shen Y. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. *Int Clin Psychopharmacol* 2001; **16**: 325–30.
- Zimbroff D, Kane J, Tamminga C, Daniel D, Mack R, Wozniak P, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. *Am J Psychiatry* 1997; **154**: 782–91.